YTHDF2 and neoplasm: Lin et al. (2020) found that YTHDF2 expression was positively associated with the expression of multiple immune checkpoint biomarkers, including CTLA-4, TIM-3, and PD-1, as well as isocitrate dehydrogenase 1, and tumor-associated macrophage factors in lower-grade glioma.